Literature DB >> 23817409

Prostate cancer: the growing evidence supporting mid-life PSA testing.

Daniel Reinhardt1, William J Catalona.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817409     DOI： 10.1038/nrurol.2013.144

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

Review 3.  Baseline prostate-specific antigen testing at a young age.

Authors:  Stacy Loeb; H Ballentine Carter; William J Catalona; Judd W Moul; Fritz H Schroder
Journal:  Eur Urol       Date:  2011-08-10       Impact factor: 20.096

4.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

5.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Authors:  Andrew J Vickers; Angel M Cronin; Thomas Björk; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  BMJ       Date:  2010-09-14

6.  Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.

Authors:  Anna Grenabo Bergdahl; Erik Holmberg; Sue Moss; Jonas Hugosson
Journal:  Eur Urol       Date:  2013-05-17       Impact factor: 20.096

7.  Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.

Authors:  David Ulmert; Angel M Cronin; Thomas Björk; Matthew F O'Brien; Peter T Scardino; James A Eastham; Charlotte Becker; Göran Berglund; Andrew J Vickers; Hans Lilja
Journal:  BMC Med       Date:  2008-02-15       Impact factor: 8.775

8.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Authors:  Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja
Journal:  BMJ       Date:  2013-04-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.